Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × defactinib × 90 days × Clear all

Phase

Phase 2 6 Phase 1 3 Phase 1/2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Low Grade Serous Ovarian Cancer 1

Interventions

pembrolizumab 112 Carboplatin 109 Cisplatin 102 Paclitaxel 84 Gemcitabine 79 Specimen Handling 72 Magnetic Resonance Spectroscopy 70 Docetaxel 59 Dexamethasone 53 Cyclophosphamide 53 Capecitabine 53 Pemetrexed 52 Oxaliplatin 52 Radiotherapy 50 Doxorubicin 47 Bevacizumab 45 Rituximab 42 durvalumab 41 Radiation 41 Fluorouracil 41 Leucovorin 37 Lenalidomide 37 Vincristine 36 atezolizumab 33 Etoposide 29 Letrozole 28 Irinotecan 28 130-nm albumin-bound paclitaxel 28 Nivolumab 27 Prednisone 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06072781 2026-03-17

RAMP 301

Verastem, Inc.

Phase 3 Recruiting

Low Grade Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡